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Atypical  hemolytic  uremic  syndrome  (aHUS)  associates  with  complement  dysregulation  caused  by  muta-
tions  and  polymorphisms  in  complement  activators  and regulators.  However,  the  reasons  why  some
mutations  in  complement  proteins  predispose  to aHUS  are  poorly  understood.  Here, we  have  investigated
the  functional  consequences  of  three  aHUS-associated  mutations  in  C3,  R592W,  R161W  and  I1157T.  First,
we  provide  evidence  that  penetrance  and  disease  severity  for these  mutations  is modulated  by  inheri-
tance  of  documented  “risk”  haplotypes  as has  been  observed  with  mutations  in other  complement  genes.
Next, we  show  that  all three  mutations  markedly  reduce  the  efﬁciency  of factor  I-mediated  C3b cleavage
when  catalyzed  by  membrane  cofactor  protein  (MCP),  but not  when  catalyzed  by  factor  H.  Biacore  anal-
ysis showed  that  each  mutant  C3b  bound  sMCP  (recombinant  soluble  MCP;  CD46)  at  reduced  afﬁnity,ED
typical hemolytic uremic syndrome
providing  a molecular  basis  for  its reduced  cofactor  activity.  Lastly,  we show  by  electron  microscopy
structural  analysis  a displacement  of the TED  domain  from  the MG ring  in  C3b  in  two  of  the  C3  mutants
that explains  these  defects  in regulation.  As  a  whole  our  data  suggest  that aHUS-associated  mutations  in
C3  selectively  affect regulation  of complement  on  surfaces  and provide  a structural  framework  to predict
the functional  consequences  of  the  C3 genetic  variants  found  in  patients.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
Hemolytic uremic syndrome (HUS) is a severe renal disorder
haracterized by Coomb’s negative microangiopathic hemolytic
nemia, thrombocytopenia and acute renal failure. Typical HUS
sually follows a diarrheal episode associated with infection by
higa toxin producing 0157:h7 Escherichia coli. Between 5 and 10%
Abbreviations: AP, alternative pathway; aHUS, atypical hemolytic uremic syn-
rome; CP, classical pathway; CR1, complement receptor 1; DAF, decay accelerating
actor; DDD, dense deposit disease; EM,  electron microscopy; FB, factor B; FD, fac-
or  D; FH, factor H; FI, factor I; KD, equilibrium dissociation constant; LP, lectin
athway; MAC, membrane attack complex; MCP, membrane cofactor protein; mt,
utant; sMCP, soluble recombinant membrane cofactor protein (MCP, CD46); SCR,
hort consensus repeat; SPR, surface plasmon resonance; wt,  wild-type.
∗ Corresponding author. Tel.: +34 918373112; fax: +34 915360432.
E-mail address: SRdeCordoba@cib.csic.es (S. Rodríguez de Córdoba).
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ttp://dx.doi.org/10.1016/j.molimm.2015.03.248
161-5890/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
of HUS cases are not associated with infection; these have a poor
prognosis with multiple recurrences and often progress to acute
renal failure, with a 30% mortality rate, reduced signiﬁcantly since
the introduction of anti-complement therapeutic Eculizumab. The
majority of cases of this atypical form of HUS  (aHUS) are associ-
ated with mutations or polymorphisms in complement proteins.
Renal injury in aHUS is caused by complement-mediated endothe-
lial damage with formation of microthrombi that occlude kidney
arterioles. Arteriole occlusion causes one of the hallmarks of HUS,
the presence of schistocytes, fragments produced as erythrocytes
break up when passing at high pressure through partially occluded
vessels.
Complement is a major component of innate immunity with
crucial roles in microbial killing, apoptotic cell clearance, immune
complex handling and modulation of adaptive immune responses.
Complement activation by three independent activation path-
ways, classical (CP), lectin (LP) and alternative (AP), results in
formation of meta-stable protease complexes, C3-convertases
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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AP, C3bBb; CP/LP, C4b2a), that cleave C3 to generate C3b.
onvertase-generated C3b forms more AP C3-convertase, pro-
iding exponential ampliﬁcation of initial activation. Binding of
3b to the C3-convertase generates a C5-cleaving enzyme (C5-
onvertase) that initiates formation of the lytic membrane attack
omplex (MAC). In health, activation of C3 is restricted and depo-
ition of C3b and further activation of complement limited to
he surface of pathogens by multiple regulatory proteins, includ-
ng factor H (Sansbury et al., 2014), C4b-binding protein (C4BP),
embrane cofactor protein (MCP), decay accelerating factor (DAF),
omplement receptor 1 (CR1) and CD59, that control complement
ctivation and prevent consumption of components by inactivating
3b or C4b (factor I-cofactor activity), dissociating the C3/C5 con-
ertases (decay accelerating activity), or inhibiting MAC formation
Walport, 2001a,b).
Mutations in genes encoding the regulatory proteins FH (CFH),
CP (MCP) and FI (CFI), and the complement activating components
actor B (CFB) and C3, are associated with aHUS; importantly, aHUS-
ssociated mutations in regulators are loss-of-function, while
utations in activators are gain-of-function (Richards et al., 2001,
003; Pérez-Caballero et al., 2001; Goicoechea de Jorge et al., 2007;
aprioli et al., 2001, 2003; Esparza-Gordillo et al., 2005; Sartz et al.,
012; Roumenina et al., 2012; Noris et al., 2003; Sa´nchez-Corral
t al., 2002; Warwicker et al., 1998; Fre´meaux-Bacchi et al., 2004,
008). We  present here the functional and structural characteriza-
ion of three C3 mutations found in the Spanish aHUS cohort. All
hree mainly impair regulation of the AP convertase on surfaces by
CP  (CD46), an effect consistent with the pathogenic mechanisms
hat characterize aHUS, and we provide a structural basis for this
mpairment. Further, we show that concurrence of these C3 muta-
ions with aHUS-conferring risk polymorphisms in the CFH and
CP  genes modulates penetrance and clinical severity of disease
n aHUS.
. Patients, materials and methods
.1. Patients
Our series of aHUS patients comprises 237 unrelated indi-
iduals, including 214 Spaniards, seven from other European
ountries, six from the USA, six from South America and four
rom Tunisia. aHUS was diagnosed by the presence of one or more
pisodes of microangiopathic hemolytic anemia and thrombocy-
openia deﬁned on the basis of hematocrit (Ht) < 30%, hemoglobin
10 mg/dl, serum lactate dehydrogenase (LDH) > 460 U/L, unde-
ectable haptoglobin, fragmented erythrocytes in the peripheral
lood smear, and platelet count <150,000/l, associated with acute
enal failure. Patients with Stx-HUS, deﬁned as the presence of
higa toxin in the stools (by the Vero cell assay) and/or of serum
ntibodies against Shiga toxin (by ELISA) and/or LPS (O157, O26,
103, O111 and O145, by ELISA) were excluded. ADAMTS13 func-
ional levels were used to exclude thrombotic thrombocytopenic
urpura.
.2. Clinical data from the families and the sporadic patient
arrying C3 mutations
.2.1. Family HUS19
There are three affected individuals (HUS19, II-1, HUS19M, I-1
nd HUS19T, I-2) in this Spanish pedigree, all of them alive. Patient
US19 is a 12y-old female who ﬁrst presented at the age of 14
onths after a respiratory infection. She has had 8 recurrences
hus far. In all these occasions she was treated with peritoneal
ialysis, plasmapheresis and plasma infusion and recovered renal
unction. The family history revealed that the mother (HUS19M) Immunology 66 (2015) 263–273
and a maternal aunt (HUS19T) also suffered an episode of aHUS
of unknown origin without recurrence. The mother presented with
aHUS when she was  6 years old and recovered completely her renal
function. The aunt had developed aHUS of unknown origin when
she was 14 months and also recovered her renal function. How-
ever, some neurological deﬁcits remained (epilepsy secondary to
hypertensive crisis) in this patient.
2.2.2. Family HUS107
Patient HUS107 is a female who belongs to another Spanish
pedigree. Her mother was  also affected. Patient HUS107 has a
healthy daughter and two unaffected brothers; one of them also
has two healthy daughters. HUS107 presented with aHUS at the age
of 35 years associated with the intake of oral contraceptives. This
episode was  complicated by neurological disorders and was treated
with antibiotics, immunosuppressive drugs (vincristine), plasma-
pheresis and plasma infusions. Currently, she has chronic renal
insufﬁciency and is supported on peritoneal dialysis. Her mother
presented at the age of 23 and also suffered aHUS associated with
neurological complications. She received a cadaveric kidney graft
at the age of 28 and died at the age of 31 with no evidence of
recurrence in the grafted kidney.
2.2.3. Patient HUS193
This patient presented with aHUS without a clear triggering
factor. The biopsy showed thrombotic microangiopathy and he
recovered completely after 8 months with haemodialysis. How-
ever, 16 years later he developed terminal renal disease. He is
currently on haemodialysis waiting for a transplant. This patient
shows permanent hypocomplementemia with low levels of C3 and
CH50 but normal levels of C4.
2.3. Mutation screening/genotyping
The patients were screened for mutations and polymorphisms
in CFH, MCP, CFI, THBD, CFB and C3 genes by automatic DNA
sequencing of PCR ampliﬁed fragments. Genomic DNA was pre-
pared from peripheral blood cells according to standard procedures
(Miller et al., 1988). Each exon of those genes was  ampliﬁed from
genomic DNA by using speciﬁc primers derived from the 5′ and
3′ intronic sequences as described (Richards et al., 2003; Pérez-
Caballero et al., 2001; Fremeaux-Bacchi et al., 2004; Miller et al.,
1988; Delvaeye et al., 2009). Automatic sequencing was performed
in an ABI 3730 sequencer using a dye terminator cycle sequencing
kit (Applied Biosystems, Foster City, CA). Copy number variations in
the CFHR1-R3 genes were analyzed by MLPA as described elsewhere
(Abarrategui-Garrido et al., 2009).
2.4. Puriﬁcation of complement components and activation
fragments
FH and factor B (FB) were puriﬁed from plasma of healthy donors
by a two-step method as described before (Tortajada et al., 2009).
Brieﬂy, ﬁltered plasma was  applied to a 5 ml afﬁnity column to
which 10 mg  of mouse anti-human FHmAb (35H9) or anti-human
FBmAb (D2) was coupled. Bound protein was eluted and polished
by gel ﬁltration on a SuperoseTM 6 10/300 column (GE Health-
care, Chalfont St. Giles, UK). sMCP (standing for soluble MCP) is
a recombinant variant of MCP  (also known as CD46) containing
the ﬁrst four SRCs (SCR1-4), lacking the membrane GPI  anchor.
sMCP was  a generous gift from our collaborator Prof. Susan Lea,
Oxford University. sMCP has been previously used to determine
binding afﬁnity with immobilized C3b (Heurich et al., 2011). All
mutant and native C3 were puriﬁed from C3102R homozygotes as
described before (Martínez-Barricarte et al., 2010). Brieﬂy, C3 was
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repared from plasma containing 20 mM EDTA and 10 mM benza-
idine. Supernatant of a 10% (w/v) sodium sulphate precipitation
as applied to a lysine-sepharose column. The ﬂow through was
ollected and applied to a DEAE-Sepharose anion exchange column.
rotein was fractionated using a NaCl gradient and C3-containing
ractions were identiﬁed by ELISA and applied to a Mono S HR 5/5
ation exchange column (GE Healthcare). Protein was eluted and
3-containing peak fractions were pooled and preserved frozen at
70 ◦C. C3b was generated by limited digestion with trypsin as
reviously described (Sánchez-Corral et al., 1989). All C3b prepara-
ions were polished by gel ﬁltration on a Superose 6 10/300 column
GE Healthcare) before being used to eliminate any detectable con-
aminants or aggregates. The protocols used were identical for
atient-derived mutant C3 and wt C3; attempts to separate mutant
rom wt C3 in patient preparations by differential elution from ion
xchange matrices were unsuccessful.
.5. Activation of C3
Puriﬁed C3 (500 g/ml), FB (50 g/ml) and FD (4 g/ml) in
0 mM sodium phosphate buffer pH 7, 100 mM NaCl and 2 mM
gCl2 were incubated in a water bath at 37 ◦C. Aliquots of 5 l were
xtracted from the mix  at 0, 0.5, 1, 2, 4, 8, 16, 32 and 60 min, mixed
ith SDS-PAGE sample buffer (2% SDS, 62.5 mM Tris, 10% glycerol
nd 0.75% bromophenol blue) to stop the reaction and loaded into a
0% reducing SDS-PAGE gel. The gels were stained using Coomassie
rilliant blue R-250 (Biorad) and digitized using a GS-800 densito-
eter (BioRad) and the MultiGauge software package (FUJIFILM).
.6. Factor H and sMCP cofactor activity for FI-mediated
roteolysis of C3b
The cofactor activities of FH and recombinant sMCP were deter-
ined in a C3b proteolytic assay using puriﬁed proteins. In brief,
3b, FH or sMCP and FI were mixed in 10 mM Hepes pH 7.5, 150 mM
aCl, 0.02% Tween 20. Final concentrations in the ﬁrst set were
50 g/ml (C3b), 17.5 g/ml (FI) and 13 g/ml (sMCP) and in the
econd set they were 76 g/ml (C3b), 3.8 g/ml (FI). Mixtures were
ncubated at 37 ◦C in a water bath and aliquots containing 2 g of
3b collected at 0, 1, 5, and 10 min. The reaction was  stopped by
ilution in 5 volumes of SDS sample buffer. Samples were analyzed
n 10% SDS-PAGE under reducing conditions. Gels were stained
ith Coomassie brilliant blue R-250 (BioRad) and proteolysis of C3b
etermined by analyzing the cleavage of the ′-chain normalizing
ith the beta chain after scanning the gels with a GS-800 calibrated
ensitometer (BioRad) and the MultiGauge software package (FUJI-
ILM).
.7. Surface plasmon resonance
Binding afﬁnities of the disease-associated C3 mutants with reg-
lators were measured by surface plasmon resonance (SRP) using
 Biacore T100 instrument (GE Healthcare). A Biacore series S-
arboxymethylated dextran (CM5) sensor chip (GE Healthcare) was
repared by immobilizing 400 RU C3b (Complement Technology)
sing standard amine coupling. The reference surface of the chip
as prepared by activating and blocking the chip surface. Exper-
ments were performed at 25 ◦C and at 20 l/min. Concentration
eries of proteins were injected as triplicates in 10 mM HEPES-
uffered saline with 3 mM EDTA and 0.05% (v/v) surfactant p20
HBSEP; GE Healthcare). Factor H (0.07 M to 4.18 M)  was ﬂowed
cross C3b for 180 s to achieve steady-state conditions, followed by
00 s dissociation in running buffer. The surface was regenerated
etween analyte injections using 1 M NaCl, 0.1 M sodium acetate,
H 4. For MCP  afﬁnity analysis, the surface was adjusted to 1500RU
3b by thioester deposition, achieved by ﬂowing FB and FD in the Immunology 66 (2015) 263–273 265
presence of Mg2+ to form C3 convertase followed by mutant C3
(or wt  C3) as substrate (Harris et al., 2007). Varying concentrations
of MCP  (0.078 M to 5 M)  were ﬂowed over the C3b surface for
90 s to achieve steady-state, followed by dissociation using running
buffer for 300 s. Data were processed using the BIAevaluation soft-
ware (GE Healthcare). Data were double-referenced by subtracting
RU shifts from the reference cell and a blank (buffer) injection;
dissociation constants were calculated using steady-state afﬁnity
analysis.
MCP-cofactor activity was assessed on the mutant C3b surface
and compared directly to the wt  C3b surface. Mutant and wt C3b
were deposited on the chip via the thioester adjusted to an equal
density of 1500RU. The C3 convertase was  formed prior to FI cleav-
age (0 s) by ﬂowing FB (2.38 M)  and FD (42 nM) in the presence
of Mg2+ over each surface separately; this conﬁrmed identical con-
vertase formation on both C3b surfaces. A ﬁxed concentration of
MCP  (0.1 M)  and FI (57 nM)  was then ﬂowed across the C3b-
coated surface at 10 l/min using four sequential injections (for
60 s, 60 s, 90 s and ﬁnally for 120 s) cleaving C3b to iC3b, resulting
in subsequent lack of afﬁnity for FB. C3 convertase formation was
measured at time zero and after each injection (% of initial conver-
tase at time 0 s equals 100%) and plotted against time of MCP/FI
exposure to the C3b surface for both mutant and wt  C3b. GraphPad
Prism Version 5.01 software was used to analyze linear regression
of C3 convertase formation (RU) versus log time (s) yielding the
slope and the goodness-of-ﬁt (r2) for each curve. The software com-
pared the slopes by calculating a P value (unpaired two-tailed) that
determines the differences in slope values for the mutant versus
the wt C3b surfaces, determining whether the lines are signiﬁ-
cantly different. The inter-experimental variation was determined
by comparing the slopes for separate wt  C3b experiments against
each other and did not differ signiﬁcantly.
2.8. Electron microscopy and image processing of C3b mutants
C3b, C3bR592W, C3bR161W and C3bI1157T were adsorbed on
carbon-coated grids and stained using 2% uranylformate. All obser-
vations were performed using a JEOL-1230 at 100 kV and images
of mutant and wt  C3b were recorded using a TVIPS F416 CMOS
camera and a ﬁnal magniﬁcation of 54926. Images of individual
molecules for all samples (6712, 7964, 7327 and 6539 images
for C3b, C3bR592W, C3bR161W and C3bI1157T, respectively) were
extracted automatically and subsequently classiﬁed and averaged
using XMIPP (Sorzano et al., 2004). Image processing and averaging
revealed that most views of the native and mutant C3b molecules
could be assigned to views of C3b in which the TED domain was
clearly either attached or displaced from the MG ring. However,
there were some images in all C3b samples that could not be
assigned to a speciﬁc conformation since they corresponded to
views of the molecule where the position of the TED domain in
reference to the MG  ring could not be determined. These images
corresponded to approximately 14% of the images in all exper-
iments (1008, 1379, 1047 and 1520 images for C3b, C3bR592W,
C3bR161W and C3bI1157T respectively), and they were discarded
from the analysis.
3. Results
3.1. Identiﬁcation of C3 mutations in aHUS patients
The Spanish aHUS cohort comprises 237 unrelated individ-
uals, including 214 Spaniards, seven other European, six USA, six
South America, four Tunisia. Three patients (HUS19, HUS107, and
HUS193; all Caucasians, Spanish origin; 1.3% of the cohort) car-
ried miss-sense mutations in heterozygosis in the C3 gene (Fig. 1).
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Fig. 1. Mutations in the C3 gene in three Spanish aHUS patients. Pedigrees of families (a) HUS19 and (b) HUS107, as well as patient (c) HUS193 are described. Individuals are
identiﬁed by numbers within each generation (in Roman numbers). Affected individuals are indicated with solid symbols. The six SNPs that comprise the CFH haplotypes
are  represented in columns. The risk-associated CFH-H3 haplotype is squared in red. The protective CFH-H2 haplotype is squared in green. Each triangle indicates one copy
of  the MCPGGAAC risk haplotype. Patients are indicated by an arrow with the appropriate code. Carriers of the heterozygous C3 mutations are indicated with a red dot. For
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ontrol sample. The corresponding amino acid sequences for the wild type and the
ranslation start site (Met +1). (For interpretation of the references to color in this ﬁ
he mutation in HUS19 located in exon 27 (c.3470T > C) causes
he amino acid substitution I1157T in the TED domain of C3. This
utation is present in the three aHUS-affected members in the
US19 pedigree, all presenting normal C3 levels (Fig. 1a; Table 1).
US107 carries a mutation in exon 4 (c.481C > T) which causes
he amino acid substitution R161W in the MG2  domain of C3 and
lso associates with normal C3 levels. The mutation was found in
he patient and her asymptomatic 10-year-old daughter (Fig. 1b).
US107 likely inherited the mutation from her aHUS-affected
other, but no DNA was available to conﬁrm this. HUS193 car-
ies a mutation in exon 14, c.1774C > T, that causes the amino acid
ubstitution R592W in the C3 MG6  domain (Fig. 1c); no family
ata were available. HUS193 shows low levels of plasma C3. The
161W, R592W and l1157T mutations have been previously asso-
iated with aHUS (Roumenina et al., 2012; Frémeaux-Bacchi et al.,
008; Schramm et al., 2015). Two of these gain-of-function C3
utations, R161W and I1157T, are relatively prevalent mutations
able 1
omplement and genetic data in individuals carrying the C3 mutations.
ID C3 levels (80–177 mg/dL) fB levels (>17 mg/dL) C4 levels (14–4
HUS19 110 26.7 21.4 
HUS19  (I-2) 95 25.7 23.9 
HUS19 (I-3) 107 25.7 15 
HUS107 91.1 33.2 13.2 
H107  (III-3)* 92.5 22.8 16.5 
HUS193 46.6 15.7 39.1 the mutated nucleotide in C3 is shown for the appropriate aHUS patient and for a
ted alleles are shown. The amino acid and nucleotide numbering is referred to the
egend, the reader is referred to the web version of this article.)
representing around 50% of the aHUS patients carrying C3 muta-
tions in Europe and Japan, respectively (Schramm et al., 2015;
Noris et al., 2010; Matsumoto et al., 2014; Maga et al., 2010;
Fan et al., 2013). Importantly, these mutations are always found
associated with aHUS. The objective of our work was to conﬁrm pre-
vious functional characterization using recombinant proteins with
plasma puriﬁed preparations of these prevalent and aHUS-speciﬁc
mutant proteins, and to extend their functional characterization
with structural data. None of the three C3 mutations described in
this report were found in controls, including 128 normal Spaniards,
or in public databases, including dbSNP, the 1000 genome database
(1092 subjects, www.1000genomes.org) and the NHLBI GO exome
sequencing projects (6503 subjects, evs.gs.washington.edu/EVS/)
(October 2014). All three patients were C3S (C3102R) homozygotes.
The heterogeneity of the kidney outcome in our patients is con-
sistent with that reported for other aHUS patients carrying the
same mutations. In fact, from the 12 patients carrying the I1157T
7 mg/dL) fH levels (5–35 mg/dL) Additional aHUS genetic factors
MCPGGAAC CFHTGTGGT CFHGATAAG
16.08 Yes (Hom) No No
10.87 Yes (Het) No Yes (Het)
19.19 Yes (Het) No Yes (Het)
22.2 Yes (Het) Yes (Hom) No
15 No Yes (Het) Yes (Het)
43.84 Yes (Het) No Yes (Het)
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Fig. 2. Activation assay of mutant C3. C3 was mixed with FB and FD and the cleavage of the C3 alpha chain to alpha′ as well as the cleavage of FB into Bb (indicated by arrows)
was  followed over time (time 0′ shows C3 control only), as shown (a) in SDS-PAGE gels for wt  C3b (top left) and each heterozygous mutant C3bR161W (top right), C3bR592W
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Mbottom left), and C3bI1157T (bottom right). It is apparent from the gels (a) and the d
utants and the wild type C3 are completely activated to C3b after 10 min  of react
esults.
utations with reported clinical descriptions, four developed a
evere disease reaching end stage renal disease (ESRD), while 8
ad a relapsing disease and/or achieved remission. The same was
bserved for patients carrying the R161W mutation; nine out of
4 reached ESRD and the remaining 5 had chronic renal disease
Roumenina et al., 2012; Noris et al., 2010; Matsumoto et al., 2014;
an et al., 2013; Fremeaux-Bacchi et al., 2013).
.2. aHUS risk polymorphisms in aHUS patients with mutations
n C3
To investigate whether clinical variability of disease in C3 muta-
ion carriers is inﬂuenced by other previously reported CFH and
CP  aHUS-associated polymorphisms, all patients and relatives
ere genotyped (Fig. 1; Table 1). Patient HUS19, who presented
 more severe clinical phenotype than her affected mother and
unt, including earlier onset and multiple recurrences, carried the
CPGGAAC risk haplotype in homozygosis, whereas her relativesometry analysis (b) illustrating the C3 cleavage as % alpha/beta chain ratio, that all
d conﬁrmed by Bb generation. The experiment was repeated twice with identical
carried a single copy of this haplotype and one copy of the aHUS-
protective CFHGATAAG haplotype (Fig. 1a). Patient HUS107 carried
the MCPGGAAC risk haplotype in heterozygosis and the CFHTGTGGT
risk haplotype in homozygosis. Her daughter (individual III-3 in
pedigree HUS107; Fig. 1b), currently healthy, carried the same
C3 mutation with both the protective CFHGATAAG haplotype and
the CFHTGTGGT risk haplotype in heterozygosis. No family members
were available for patient HUS193 who had a slowly develop-
ing disease and carried both the MCPGGAAC risk haplotype and the
CFHCATAAG protective haplotype in heterozygosis (Fig. 1c).
3.3. Puriﬁcation of C3 mutant proteins
C3 proteins were puriﬁed from plasma of appropriate mutant
carriers; these individuals were heterozygotes and therefore C3
preparations were a mix  of mutant and wild-type (wt) C3. Pro-
teomic analysis of C3 proteins puriﬁed from patients conﬁrmed
the presence of mutant C3 (Supplementary Table 1); SDS-PAGE
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Fig. 3. Cofactor activity of sMCP and FH for mutant C3b. (a) Recombinant sMCP cofactor activity assay shows that all heterozygous C3b mutants are more resistant than wt
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(3b  to inactivation by FI in the presence of sMCP. After 10 min, only half of the mut
nactivated by FI in the presence of FH at similar rates and to similar degrees.
nder reducing conditions separated the C3b -chains correspond-
ng to wt and mutant alleles in C3 from patients carrying the
592W and R161W mutations enabling us to estimate that mutant
3 protein represented approximately 50% of total circulating
3 in these patients (Supplementary Fig. 1). By using a mixture
f wt and mutant protein preparation for our analyses, rather
han making homogenous recombinant proteins, we provide a
learer picture of the in vivo functional effect as it presents in the
atients.
ig. 4. Afﬁnity assays of MCP  and FH for the mutant C3 mutants. Binding afﬁnities of C
lasmon resonance (SRP). (a) Recombinant sMCP binding afﬁnities (KD, M)  with C3bR5
3bI1157T (0.94 ± 0.06 M;  P < 0.0001, n = 3); all showing weaker afﬁnity compared to wt
2.45 ± 0.05 M;  P < 0.0001, n = 3), C3bR161W (2.39 ± 0.07; P < 0.0001, n = 3), and C3bI1157T (
KD  0.96 ± 0.04 M,  n = 9). P-values (two-tailed, unpaired t-test; depicted as asterisk) refe
KD,  M; Mean ± standard deviation) values of recombinant sMCP or FH binding to immo157T was  cleaved. (b) FH cofactor activity assay shows that mutant and wt  C3b are
3.4. aHUS-associated C3 mutants are activated normally by the
AP C3 convertase
The three C3 mutant proteins were incubated with FB and
FD at 37 ◦C and cleavage to C3b analyzed by SDS-PAGE. For
comparison, wt C3 puriﬁed from pooled normal plasma at the
same time and using the same method was  included. Coomassie-
stained gels and densitometry analyses are shown in Fig. 2.
All three aHUS-associated C3 mutants were activated to C3b
3b mutants with complement regulators MCP  and FH were measured by surface
92W (0.71 ± 0.02 M; P = 0.0006, n = 3), C3bR161W (0.93 ± 0.06; P < 0.0001, n = 3), and
 C3b (KD 0.57 ± 0.04 M,  n = 6). (b) FH binding afﬁnities (KD, M)  with C3bR592W
1.42 ± 0.02 M;  P < 0.0001, n = 3); all showing weaker afﬁnity compared to wt C3b
r to the comparison of each mutant KD versus wt KD. (c) Table summarizing afﬁnity
bilized wt  and mt  C3b.
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Fig. 5. MCP  cofactor assays for the C3 mutants. Sensorgrams show C3 convertase formation before (0 s) and after sequential (+60 s, 60 s, 90 s, 120 s) inactivation of C3b by
sMCP  and CFI. At time 0 s, formation of both mutant and wt  C3 convertases are identical. C3 convertase formation (RU, maximum indicated by asterisk) remaining after
sequential exposure to sMCP/FI relative to initial convertase (time zero) is shown for (a) C3bR161W, (b) C3bR592W, and (c) C3bI1157T (solid black line) compared to wt C3b (dashed
gray  line). Linear graph (b, d, f) showing percentage C3 convertase formation vs log total exposure time (s) after each interval of C3b surface exposure to sMCP/FI. Linear
regression analysis gives the slope for each curve, which illustrates the rate of C3b inactivation over time. Mutant (b) C3bR161W (slope: −51.2 ± 2.85, r2 = 0.9939, P = 0.02), (d)
C3bR592W (slope: −54.2 ± 1.3, r2 = 0.9988, P = 0.003) and (f) C3bI1157T (slope: −43.5 ± 0.5, r2 = 0.9997, P = 0.001) is resistant to sMCP/FI-mediated inactivation compared to wt
C howe
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b3b  (slope: −66.5 ± 2.6, r2 = 0.9970). Individual wt C3b slopes were compared and s
y the AP C3 convertase normally and at similar rates to
t C3.
.5. Cofactor analysis of aHUS-associated C3 mutants reveals
esistance to regulation by MCP  but not FH
C3 preparations from each of the three individuals, and nor-
al  C3, were converted to C3b using trypsin (Sánchez-Corral et al.,
989) and used to test cofactor activities of FH and MCP  for FI-
ediated C3b cleavage. Identical amounts of each C3b preparation
ere incubated with FI and either puriﬁed FH or soluble recom-
inant MCP  (sMCP). All three aHUS mutant C3b proteins wered no signiﬁcant difference (n = 3, P = 0.91).
inactivated by FI in the presence of FH at a rate indistinguishable
from that of wt C3b (Fig. 3b). In contrast, all three aHUS mutant
C3b preparations were partially inactivated by sMCP (Fig. 3a). An
average of 50% of C3bI1157T and 70% of C3bR592W and C3bR161W
was cleaved, compared to almost complete cleavage of wt C3 after
10 min. Considering that approximately 50% of the C3 in prepa-
rations from patients carrying the R592W and R161W mutations
is mutant protein, these assays demonstrate signiﬁcant resistance
of the C3bR592W and C3bR161W mutant proteins to inactivation by
MCP, almost complete in the case of the C3bI1157T mutant. These
data suggest that defective surface regulation is the primary con-
sequence of these aHUS-associated C3 mutations.
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Fig. 6. EM analyses of the overall structure of C3b, C3bR592W, C3bR161W and C3bI1157T. (a) Galleries of three representative average images of wt C3b and heterozygous mutant
C3bI1157T, C3bR161W and C3bR592W obtained by EM at 50 mM NaCl. The total number of molecules analyzed and the percentage of single molecule images assigned to each
conformation after image processing is indicated, together with the statistic signiﬁcance of their differences. A cartoon model for each of the conformations based on the
structure of C3b is shown (TED domain highlighted in dark gray color). (b) Cartoon model of the interaction of the SCRs 1–4 of FH (FH1-4; green color) and SCRs 1–4 of MCP
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.6. C3b mutants bind MCP  and FH with lower afﬁnity compared
o wt
To determine whether mutant C3b binds MCP, each C3b prepa-
ation was immobilized as described in methods and sMCP ﬂowed
ver the surface. The afﬁnity of mutants C3bR592W, C3bR161W and
3bI1157T was reduced compared with wt C3b (Fig. 4a). In comple-
entary experiments testing capacity of MCP  to act as a cofactor
n the FI-mediated inactivation of surface-bound C3b (Fig. 5a–f),
e found that this decreased binding impaired MCP cofactor activ-
ty. MCP-cofactor activity was most impaired for C3bI1157T, directly
orresponding to the cofactor activity results (Fig. 3a).
The afﬁnity of all mutant C3b preparations for FH was reduced
ompared with wt C3b (Fig. 4b) but FH/FI cleavage assays showed
o signiﬁcant difference in FH-cofactor activity for C3b mutants
ompared to wt (Fig. 3b) in accordance with previous reports
Roumenina et al., 2012; Frémeaux-Bacchi et al., 2008).
.7. Structural analysis of the C3b mutants
C3b shows characteristic electron microscopy (EM) features that
an be directly extrapolated to the atomic structure of C3b (Torreira
t al., 2009; Nishida et al., 2006; Janssen et al., 2006). The most fre-
uent view, by comparison to crystal structures, corresponds to a
elatively compact conformation in which the TED domain is visu-
lized attached to the MG  ring. This conformation represents >90%
f EM images in native C3b, likely maintained by charge interac-
ions between the domains because increasing salt concentration
bove 50 mM NaCl resulted in dramatic conformational change
ith TED domain detachment from the MG  ring (not shown). We
ave used these EM analyses to determine whether the overall
tructure of C3b is altered in the C3bR592W, C3bR161W and C3bI1157T
utants. C3bR592W was indistinguishable from wt  C3b with only a
inor proportion of EM images (6% compared to 9% in wt  C3b) pre-enting a detached TED domain (Fig. 6a). In contrast, EM analysis of
utants C3bI1157T and C3bR161W showed 68% and 36% respectively
f EM images had TED displaced from MG domain. Considering
hat mutant C3 protein in the C3bI1157T and C3bR161W preparations the one with the delocalized TED domain on the lower one, based on the crystal
 C3b and MCP (see also Fig. 7). (For interpretation of the references to color in this
represents approximately 50% of the C3b molecules, these data
suggest that both I1157T and R161W mutations impact MG/TED
domain interaction and overall C3b conformation, I1157T mutation
having the strongest effect. These are important ﬁndings because a
displaced TED has direct consequences for interaction of C3b with
the regulators FH (Wu et al., 2009) and MCP  (Persson et al., 2010)
(Figs. 6b and 7). We  recently postulated that TED displacement con-
tributes to the increased resistance of properdin-C3bBb complexes
(Alcorlo et al., 2013) and iC3b (Alcorlo et al., 2011) to accelerated
decay or inactivation by complement regulators.
The I1157T and R161W mutations localize to the TED and MG2
domains facing the MG1  and CUB domains respectively, and thus
it is conceivable that these C3 mutations could affect, directly or
indirectly, stability of contacts between the CUB-TED region and the
MG ring. TED domain displacement in the C3bI1157T and C3bR161W
mutants supports reduced stability of the contacts, which in turn
provides a plausible explanation for their increased resistance to
inactivation by MCP.
4. Discussion
aHUS is a rare, life-threatening renal pathology associated with
complement dysregulation and endothelial cell injury, culminating
in formation of microthrombi that occlude small vessels in kid-
ney leading to severe renal impairment (Noris et al., 2009). aHUS
has a strong genetic component (Pickering et al., 2007; Rodríguez
de Córdoba et al., 2014) and is strongly associated with polymor-
phisms and mutations in activators (C3 and FB) and regulators
(MCP, FI and FH) of the complement AP. We  identiﬁed six carriers
of C3 mutations (Fig. 1). All were heterozygotes and all, except-
ing a 10-year-old child in pedigree HUS107, have developed aHUS.
None of these patients carried additional mutations in CFH, MCP,
CFI or CFB, or CFH-CFHR1/5 rearrangements. Disease severity var-
ied considerably among the patients (Supplementary materials
and methods). To investigate whether this clinical variability was
inﬂuenced by other aHUS genetic risk factors, patients and fam-
ily members were genotyped for CFH and MCP  aHUS-associated
polymorphisms (Caprioli et al., 2003; Esparza-Gordillo et al., 2005;
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Fig. 7. Structural implications for the aHUS-associated C3 mutations. (a) Cartoon diagram (two views) of C3b in complex with the four SCRs of FH (PDB 2WII) and with MCP
(3O8E) aligned at SCR3 with respect to FH. In green are the heterozygous mutations in C3 described in this report and those described earlier by Frémeaux-Bacchi et al.
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haracterized thus far (Martínez-Barricarte et al., 2010). (b) Enlarged image of the C
f  the references to color in this ﬁgure legend, the reader is referred to the web ver
ánchez-Corral et al., 1989). Disease severity correlated with the
resence of risk haplotypes in CFH and MCP  in patients HUS19
nd HUS107. Although the number of patients reported here is
oo small to draw deﬁnitive conclusions, the data suggest that the
HUS phenotype associated with the C3 mutations is modulated by
ommon polymorphisms conferring risk or protection from aHUS,
s demonstrated before for mutations in other complement genes
Esparza-Gordillo et al., 2005, 2006; Abarrategui-Garrido et al.,
009; Martinez-Barricarte et al., 2008). This observation is consis-
ent with the recent demonstration that severity and penetrance of
HUS in C3 mutation carriers in the French cohort was  inﬂuenced
y the presence of the MCP  risk haplotype (Roumenina et al., 2012),
nd that risk and protective CFH haplotypes impacted on risk in two
arge aHUS pedigrees (Sansbury et al., 2014).
MCP  and FH are vital cofactors for FI-mediated inactivation of
3b by cleavage of the CUB domain. Previous studies of mutations in
H, MCP  and C3 suggested that aHUS is caused by surface dysregula-
ion of complement, while ﬂuid phase regulatory capacity remains
ormal (Rodríguez de Córdoba et al., 2014). Data presented in this only mutation linked to dense deposit disease (DDD) that has been functionally
gion including the C3bR592W, C3bR161W and C3bI1157T mutations. (For interpretation
f this article.)
report support these suggestions. We  illustrate here that despite
our C3b mutants have reduced afﬁnity for both FH and MCP, they
show impaired regulatory function only for MCP. This is consis-
tent with previous reports, testing several C3 mutations expressed
as recombinant proteins, in which a decreased afﬁnity for MCP
and/or FH was  observed by the majority of the mutant C3b pro-
tein tested. Importantly, the R161W mutant was  included in those
studies and when FI-cofactor activity by FH and MCP  was  tested
in this mutant it was found that only the regulation by MCP  was
impaired (Roumenina, et al., 2012, Frémeaux-Bacchi et al., 2008;
Schramm et al., 2015; Maga et al., 2010).
Alignment of MCP1-4 and FH1-4 structures onto C3b highlights
important differences between these regulators regarding their
interaction interfaces on C3b (Fig. 7a). SCR3 and SCR4 in both FH
and MCP  interact with overlapping areas of C3b spanning a region
including MG2/CUB and MG1/TED domains; however, MCP SCR3-4
appears signiﬁcantly more bent (Persson et al., 2010). Notably this
region of C3b is the location of our aHUS-associated C3 mutations
and the four C3 mutations previously described (Roumenina et al.,
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012; Frémeaux-Bacchi et al., 2008), all with differential impact
n FH and MCP  (Fig. 7a). Unlike their homologues in FH, SCR1 and
CR2 in the MCP  hockey stick shape are not in contact with C3b
Wu et al., 2009; Persson et al., 2010; Gordon et al., 1995). Consis-
ent with these interactions, MCP  SCR4 is particularly important for
ofactor function (Persson et al., 2010), whereas FH cofactor activity
s largely lost without SCR1, implying that the interaction of SCR1
nd SCR2 with C3b is crucial for FH regulatory activities (Gordon
t al., 1995). Overall, these data show that the location of a muta-
ion in C3 dictates its impact on FH and MCP  interaction with C3b
nd therefore on ﬂuid phase or surface regulation. This provides an
xplanation for the distinction between the three aHUS-associated
3 mutations described here (R592W, R161W and I1157T) and the
nly functionally characterized dense deposit disease-associated
3 mutant (C3del923DG) (Martínez-Barricarte et al., 2010); they
peciﬁcally impact the interactions between C3b and MCP or C3b
nd FH, respectively (Fig. 7).
A major novel ﬁnding from EM is that two of the mutations
R161W and I1157T) disrupt the overall structure of C3b by dislo-
ating the TED domain from the MG  ring, resulting in increased TED
exibility (Fig. 6). A structural model (Fig. 7b) illustrates that these
utations are close enough to contact regions between MG2/CUB
nd MG1/TED domains, respectively, to impair inter-domain inter-
ctions. This observation reinforces the concept that TED position
s an important modulator of C3b interactions with complement
egulators, as previously proposed for properdin-C3bBb complexes
Alcorlo et al., 2013) and iC3b (Alcorlo et al., 2011) to explain
esistance to accelerated decay and inactivation by complement
egulators. TED domain ﬂexibility and dislocation away from the
G1–MG8 domain core has been shown for hydrolysed C3 (C3H2O)
Li et al., 2010), perhaps explaining differences between C3b and
3H2O in their interactions with complement regulators; for exam-
le, the afﬁnity of FH for C3H2O is several fold weaker than the
3b–FH interaction (Heurich et al., 2011).
A recent report used analytical centrifugation, X-ray and neu-
ron scattering to show TED domain detachment from MG1
omain when NaCl concentration was raised; a salt-bridge between
esidues E1031 in TED and R102 in MG1  domain was implicated
n the interaction (Rodriguez et al., 2014). Our data are consistent
ith these results, EM images revealing conformational hetero-
eneity in positioning of the TED domain with respect to the MG
ing and demonstrating that mutations around TED/MG contact
egions dislocate the interaction resulting in increased TED ﬂexi-
ility and altered C3b conformation. The R592W mutation located
n C3b MG6  does not disrupt TED location (Fig. 7); its functional
mpact thus involves a different mechanism, perhaps directly dis-
upting the C3b interaction surface thereby reducing FH and MCP
fﬁnity and MCP  regulatory capacity.
In conclusion, we report functional, biochemical and structural
xplanations of the mechanism of pathogenicity of three aHUS-
ssociated C3 mutations; all three mainly impair the regulatory
ction of MCP. These data further support the contention that aHUS
s caused by surface-restricted AP dysregulation and illustrate the
ower of combining genetic, functional and structural studies of
athogenic mutations to explain mechanisms of disease.
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